William Blair Has Pessimistic Outlook of Hologic Q1 Earnings

Hologic, Inc. (NASDAQ:HOLX - Free Report) - William Blair dropped their Q1 2025 earnings per share (EPS) estimates for shares of Hologic in a research report issued to clients and investors on Monday, November 11th. William Blair analyst A. Brackmann now anticipates that the medical equipment provider will post earnings of $1.00 per share for the quarter, down from their previous forecast of $1.02. The consensus estimate for Hologic's current full-year earnings is $4.27 per share. William Blair also issued estimates for Hologic's FY2026 earnings at $4.62 EPS.

A number of other research firms have also recently weighed in on HOLX. Evercore ISI upped their price target on Hologic from $78.00 to $82.00 and gave the stock an "in-line" rating in a report on Tuesday, October 1st. Needham & Company LLC reaffirmed a "buy" rating and set a $90.00 price target on shares of Hologic in a report on Tuesday, October 15th. Raymond James boosted their price objective on shares of Hologic from $93.00 to $95.00 and gave the stock an "outperform" rating in a report on Tuesday, November 5th. JPMorgan Chase & Co. lifted their target price on Hologic from $92.00 to $94.00 and gave the stock an "overweight" rating in a research report on Tuesday, November 5th. Finally, Royal Bank of Canada increased their price target on Hologic from $86.00 to $89.00 and gave the company a "sector perform" rating in a report on Tuesday, November 5th. Six equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $89.25.

Hologic Stock Down 0.7 %

Shares of NASDAQ HOLX traded down $0.58 on Wednesday, hitting $79.18. The company had a trading volume of 1,417,388 shares, compared to its average volume of 1,592,564. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49. Hologic has a 12-month low of $67.59 and a 12-month high of $84.67. The firm has a market capitalization of $18.39 billion, a P/E ratio of 24.02, a PEG ratio of 2.52 and a beta of 0.98. The business has a 50 day moving average of $80.88 and a two-hundred day moving average of $78.22.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, meeting analysts' consensus estimates of $1.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The business had revenue of $987.90 million for the quarter, compared to the consensus estimate of $978.25 million. During the same quarter last year, the firm posted $0.89 EPS. The business's revenue for the quarter was up 4.5% compared to the same quarter last year.

Hedge Funds Weigh In On Hologic

Hedge funds and other institutional investors have recently modified their holdings of the company. Price T Rowe Associates Inc. MD grew its stake in shares of Hologic by 77.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 6,297,197 shares of the medical equipment provider's stock worth $490,931,000 after purchasing an additional 2,753,016 shares in the last quarter. FMR LLC raised its position in shares of Hologic by 64.0% during the 3rd quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider's stock worth $453,940,000 after buying an additional 2,174,093 shares in the last quarter. Swedbank AB bought a new stake in shares of Hologic during the 1st quarter worth about $120,827,000. Black Creek Investment Management Inc. lifted its stake in shares of Hologic by 60.9% in the 2nd quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider's stock worth $173,669,000 after acquiring an additional 885,524 shares during the period. Finally, Mackenzie Financial Corp boosted its holdings in shares of Hologic by 1,023.3% in the second quarter. Mackenzie Financial Corp now owns 895,699 shares of the medical equipment provider's stock valued at $66,506,000 after acquiring an additional 815,960 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company's stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.